InveniAI Launches Suite of Products Powered by AlphaMeld™, an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences - CIMeld™, an AlphaMeld™ powered product for competitive/business intelligence, is set to launch at PharmaCI USA 2019 - Tailored suite of products to address high value questions accelerating...

InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU  Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...

Medical Imaging Reagents Market to Reach US$18.5 Billion in 2019 owing to Rising Demand for Diagnostic Imaging Technologies: Transparency Market Research Albany - NY, Sept. 11, 2015 (GLOBE NEWSWIRE) -- A new Transparency Market Research report states that the global medical imaging reagents market stood at US$10.3 billion in 2012 and is expected to...

NeuPharma Announces the Initiation of Phase I Clinical Trial of Novel Na+/K+-ATPase Inhibitor RX108 in Cancer Patients SUZHOU, China, June 08, 2015 (GLOBE NEWSWIRE) -- Suzhou NeuPharma Co., Ltd. today announced that it has initiated the first-in-human Phase I clinical trial of RX108 in Australia.  RX108 is a...